Low Body Weight Linked to PML Risk With Natalizumab in MS Low Body Weight Linked to PML Risk With Natalizumab in MS

Results of a new study suggest that low body mass may be a risk factor for progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news